Janux Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $439 | $8,897 | $1,252 | $2,461 |
Gross Profit | 439 | 8,391 | 720 | 1,930 |
EBITDA | -35,842 | -13,316 | -19,629 | -15,606 |
EBIT | -36,352 | -13,822 | -20,161 | -16,137 |
Net Income | -28,059 | -5,959 | -14,760 | -11,758 |
Net Change In Cash | 439 | 8,897 | 1,252 | 2,461 |
Free Cash Flow | -2,256 | -10,116 | -15,034 | -10,416 |
Cash | 26,754 | 14,662 | 212,803 | 19,205 |
Basic Shares | 54,628 | 54,451 | 49,049 | 46,683 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $8,083 | $8,612 | $3,637 | $380 |
Gross Profit | -46,839 | 8,612 | 3,637 | -13 |
EBITDA | -71,024 | -66,250 | -32,816 | -4,830 |
EBIT | -72,979 | -67,091 | -32,929 | -4,843 |
Net Income | -58,293 | -54,154 | -32,559 | -5,255 |
Net Change In Cash | 8,083 | 8,612 | 3,637 | 380 |
Cost of Revenue | 15,844 | 28,585 | ||
Free Cash Flow | -52,425 | -49,367 | -18,458 | -4,369 |
Cash | 19,205 | 51,426 | 35,582 | 7,813 |
Basic Shares | 44,016 | 41,469 | 41,243 | 41,611 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.51 |
2024-06-30 | -$0.11 |
2024-03-31 | -$0.30 |
2023-12-31 | -$0.25 |
